We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

81 hedge funds and large institutions have $164M invested in Protagonist Therapeutics in 2019 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 15

38% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 13

13.19% more ownership

Funds ownership: 72.06% → 85.25% (+13%)

7% more funds holding

Funds holding: 76 → 81 (+5)

28% less capital invested

Capital invested by funds: $228M → $164M (-$64M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
81
Holders Change
+5
Holders Change %
+6.58%
% of All Funds
1.6%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
18
Increased
34
Reduced
15
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$16.9M
2
SFM
Sphera Funds Management
Israel
+$6.26M
3
BlackRock
BlackRock
New York
+$4.75M
4
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board
Ontario, Canada
+$2.48M
5
O
OrbiMed
New York
+$1.9M

Top Sellers

Rank Fund Capital Flow
1
VMI
VHCP Management III
New York
-$9.85M
2
ACP
Acuta Capital Partners
California
-$5.03M
3
VMI
VHCP Management II
New York
-$3.92M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.95M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1.89M
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
26
Squarepoint
New York
$656K +$90.1K +9,069 +11%
Jacobs Levy Equity Management
27
Jacobs Levy Equity Management
New Jersey
$647K +$775K +78,021 +565%
BCM
28
Bridgeway Capital Management
Texas
$643K – – –
WG
29
Winton Group
United Kingdom
$633K +$524K +52,732 +142%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$589K +$61.4K +6,180 +8%
VMI
31
VHCP Management III
New York
$571K -$9.85M -991,419 -92%
IC
32
Ikarian Capital
Texas
$552K +$778K +78,326 New
Allianz Asset Management
33
Allianz Asset Management
Germany
$507K -$410K -41,275 -36%
GCP
34
GSA Capital Partners
United Kingdom
$474K +$667K +67,186 New
OAM
35
Oxford Asset Management
United Kingdom
$438K -$1.1M -110,540 -64%
Prudential Financial
36
Prudential Financial
New Jersey
$365K +$513K +51,690 New
Russell Investments Group
37
Russell Investments Group
United Kingdom
$334K -$291K -29,267 -38%
Charles Schwab
38
Charles Schwab
California
$309K +$31.2K +3,139 +8%
PP
39
PDT Partners
New York
$306K +$236K +23,785 +121%
T. Rowe Price Associates
40
T. Rowe Price Associates
Maryland
$300K +$150K +15,151 +55%
Wells Fargo
41
Wells Fargo
California
$237K +$74.5K +7,504 +29%
Morgan Stanley
42
Morgan Stanley
New York
$235K -$881K -88,674 -73%
VMI
43
VHCP Management II
New York
$227K -$3.92M -394,570 -92%
WCM
44
Weld Capital Management
New York
$222K +$313K +31,488 New
Deutsche Bank
45
Deutsche Bank
Germany
$197K +$79.6K +8,015 +40%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$187K – – –
SIM
47
Spark Investment Management
New York
$168K +$237K +23,900 New
FSA
48
Franklin Street Advisors
North Carolina
$166K – – –
State of Wisconsin Investment Board
49
State of Wisconsin Investment Board
Wisconsin
$161K – – –
AQR Capital Management
50
AQR Capital Management
Connecticut
$160K – – –
1
2
3 4

PTGX Hedge Fund Activity: Q4 2019 in Review

81 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2019, worth a combined $164M — down 28% from $228M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new PTGX positions and 13 closed out — a net gain of 5 holders — while 34 added to existing stakes and 15 trimmed.

The largest buyer was RTW Investments, adding an estimated $16.9M. The largest seller was VHCP Management III, cutting an estimated $9.85M.

  • 81 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2019, up from 76 in Q3 2019.
  • Funds reported $164M of Protagonist Therapeutics stock for Q4 2019, down 28% quarter-over-quarter.
  • 18 funds opened new Protagonist Therapeutics positions in Q4 2019 and 13 closed out, a net change of +5 holders.
  • The largest Protagonist Therapeutics buyer in Q4 2019 was RTW Investments, an estimated $16.9M added.
  • The largest Protagonist Therapeutics seller in Q4 2019 was VHCP Management III, an estimated $9.85M sold.

Based on aggregated 13F filings for Q4 2019.